Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Incyte Corporation
TransThera Sciences (Nanjing), Inc.
AstraZeneca
Xencor, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
TransThera Sciences (Nanjing), Inc.
Exelixis
HiberCell, Inc.
Eastern Cooperative Oncology Group
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
Bayer
Incyte Corporation
Gilead Sciences
Institut Bergonié
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Celgene
MedImmune LLC
AbbVie
SWOG Cancer Research Network
Swiss Cancer Institute
Pfizer
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of Kansas Medical Center
Amgen
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
Northwestern University
Santa Maria Biotherapeutics
Dana-Farber Cancer Institute
Novartis
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
University of Southern California
Fox Chase Cancer Center
AHS Cancer Control Alberta
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)